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Full list of Inclusion and Exclusion criteria Inclusion:
Participants were included in the study if the met the following criteria:
 Participant is willing and able to give informed consent for participation in the study.  Aged 18 years or above.  Body Mass Index ≥30 kg/m 2 .
 Likely to benefit from weight loss in the Primary Care physician's opinion.
Exclusion:
The following criteria were used to exclude individuals for whom weight loss might not be safe, those who may have difficulty adhering to TDR intervention, or those with medical conditions that were a contraindication to the TDR programme.
 Currently or recently (within 3 months of study entry) attended a weight management programme or currently participating in another weight loss study.
 Had bariatric surgery, or scheduled bariatric surgery.
• Pregnant, breastfeeding, or planning to become pregnant during the course of the study.
• Receiving insulin therapy • Heart attack or stroke within the last 3 months • Heart failure of grade II New York Heart Association and more severe • Angina, arrhythmia, including atrial fibrillation or prolonged QT syndrome • Taking MAOI medication • Taking anticoagulant medication (e.g. warfarin)
• Taking varenicline (smoking cessation medication)
• Chronic renal failure of stage 4 or 5 • Active liver disease (except NAFLD) a past history of hepatoma or within 6 months of onset of acute hepatitis. • People having active treatment for cancer other than skin cancer treated with curative intent by local treatment only or people taking hormonal or other long-term secondary prevention treatment after initial cancer treatment.
• Active treatment or investigation for possible or confirmed gastric or duodenal ulcer.
Maintenance treatment with acid-suppression is not a contra-indication.
• Porphyria • Scheduled for surgery within 12 months • A member of household is already enrolled in the study • Unwilling to provide blood samples • Patients that the Primary Care physician judges not able to meet the demands of either treatment programme or measurement schedule. This may include severe medical problems not listed above or severe psychiatric problems including substance misuse that make following the treatment programme or adhering to the protocol unlikely.
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Figure S1: Treatment effect by sub-groups *IMD decile is an indicator of deprivation, with decile 1 being most deprived, and decile 10 the least deprived. IMD groups were compared using median split. IMD was not a pre-specified sub-group analysis, and was added after the statistical analysis plan was written, but before the primary analysis was conducted.
Primary analysis
Practice 10
Practice 9
Practice 8
Practice 7
Practice 6
Practice 5
Practice 4
Practice 3 
Difference in weight change from baseline (kg) at 12 months (95% CI)

Favours intervention Favours control
Unadjusted weight change from baseline* -2.1 ± 6.0 -8.3 ± 9.6 -2.7 ± 6.3 -10.2 ± 9.2 -3.5 ± 8.2 -10.2 ± 9.7 -3.1 ± 7.0 -10.7 ± 9.6
Difference between groups † -6.1 (-8.0, -4.3) -7.5 (-9.4, -5.6) -6.4 (-8.5, -4.4) -7.5 (-9.8, -5.1) p-value <0.0001 <0.0001 <0.0001 <0.0001 *Mean weight (kg) ± SD † Adjusted mean difference (kg) (95% CI) using linear mixed effects model with fixed effects for randomisation group, baseline weight, visit and randomised group x visit interaction. Random effects accounting for practice and participant and within subject variance covariance matrix specified as unstructured. Age and sex were included as covariates as baseline values were predictive of missingness. 
